Synaffix Aims For Top ADC Tech Provider Spot After Inking MacroGenics Deal
Pact Potentially Worth $586m
The Dutch firm’s dream to become the number one antibody drug conjugate technology provider by 2023 has been bolstered by a flurry of recent strategic collaborations, including one with MacroGenics.
You may also be interested in...
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.